Drug news
FDA advisory committee does not recommend buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain.- Insys Therapeutics.
Insys Therapeutics, Inc. confirmed that an expert panel convened by the FDA voted not to recommend approval of the company�s New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins